Warning! GuruFocus detected
2 Severe warning signs
with IKT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Inhibikase Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45719W2052
Share Class Description:
IKT: Ordinary SharesDescription
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.37 | |||||
| Equity-to-Asset | -0.12 | |||||
| Debt-to-Equity | -0.27 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -22 | |||||
| 3-Year EPS without NRI Growth Rate | -19.3 | |||||
| 3-Year FCF Growth Rate | -60.2 | |||||
| 3-Year Book Growth Rate | -32.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 47.19 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.85 | |||||
| 9-Day RSI | 53.63 | |||||
| 14-Day RSI | 50.46 | |||||
| 3-1 Month Momentum % | -7.19 | |||||
| 6-1 Month Momentum % | 147.5 | |||||
| 12-1 Month Momentum % | 34.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.85 | |||||
| Quick Ratio | 0.85 | |||||
| Cash Ratio | 0.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -54.6 | |||||
| Shareholder Yield % | -2.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -262 | |||||
| ROA % | -172.66 | |||||
| ROIC % | -2093.93 | |||||
| 3-Year ROIIC % | 1343.08 | |||||
| ROC (Joel Greenblatt) % | -7734.77 | |||||
| ROCE % | -266.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -8.61 | |||||
| EV-to-Forward-EBIT | -0.08 | |||||
| EV-to-EBITDA | -8.62 | |||||
| EV-to-Forward-Revenue | 1358.04 | |||||
| EV-to-FCF | -10.02 | |||||
| Earnings Yield (Greenblatt) % | -11.61 | |||||
| FCF Yield % | -10.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IKT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Inhibikase Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.13 | ||
| Beta | 1.23 | ||
| 3-Year Sharpe Ratio | 0.16 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 119.44 | ||
| 14-Day RSI | 50.46 | ||
| 14-Day ATR ($) | 0.22789 | ||
| 20-Day SMA ($) | 2.269 | ||
| 12-1 Month Momentum % | 34.39 | ||
| 52-Week Range ($) | 1.12 - 4.2 | ||
| Shares Outstanding (Mil) | 72.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibikase Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibikase Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inhibikase Therapeutics Inc Frequently Asked Questions
What is Inhibikase Therapeutics Inc(IKT)'s stock price today?
The current price of IKT is $2.38. The 52 week high of IKT is $4.20 and 52 week low is $1.12.
When is next earnings date of Inhibikase Therapeutics Inc(IKT)?
The next earnings date of Inhibikase Therapeutics Inc(IKT) is 2025-03-27 Est..
Does Inhibikase Therapeutics Inc(IKT) pay dividends? If so, how much?
Inhibikase Therapeutics Inc(IKT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers